More recently, a mouse model incorporating liver-specific mutant Kras expression and Pten deletion demonstrated mixed ICC and HCC when heterozygous Pten deletion was present, but pure ICC development with Kras activation and homozygous Pten deletion [64]. This evidence concerns the gene KRAS and intrahepatic cholangiocarcinoma.